ALK-Abelló
Investor NewsALK to present at Jefferies 2014 Global Healthcare Conference in London Copenhagen, 2014-11-11 17:55 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Jefferies 2014 Global Healthcare Conference at the Waldorf Hilton Hotel in London. Flemming Pedersen, CFO & EVP, will provide an overview of the Company and its key programmes on Wednesday, 19 November at 3.00 p.m. GMT. ALK-Abelló A/S For further information please contact: Investor Relations:
Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Janet Dally, tel. +1 609-466-0466 Press:
Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143 About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii to commercialise sublingual allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net. | 